Posted: 3 October 2021
Minimum data is due by: 16 February 2022
The objective of the 2021 GBM AGILE Grant Opportunity is to provide a grant of financial assistance to support an Australian medical research and medical innovation project that aims to improve outcomes for Australians diagnosed with brain cancer, specifically Glioblastoma Multiforme (GBM), by leading, co-ordinating and managing the implementation and evaluation of the Australian arm of the GBM AGILE clinical trial.
The intended outcome of the research funded by this grant opportunity is to improve the health and wellbeing of Australians by:
This grant opportunity is being administered by NHMRC on behalf of the Australian Government Department of Health.